The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases andsurvival would be quantified in patiens chronically treated with antihistamines oramantadine, with the aim of determining the role of antihistamines and amantadine in theevolution of COVID19.
BACKGROUND: According to previous reports, all 84 eldery residents in nuersing homes in
Yespes (Toledo, Spain), had a 100% of positive serology for COVID-19 in June 2020, but
none died nor hospitalized after receiving early treatment with antihistamines. Other
case reports have suggested a protective role of amantadine, since infected patients
showed a very mild COVID19 infection.
OBJECTIVES.Determine the role of antihistamines and amantadine in the evolution of
COVID19.
METHODS. Describe the rate of hospitalization, ICU and survival among COVID 19 cases
having antihistamines and amantadine as chronic treatments.
The rates would be stratified by age groups and compared with the same age groups of the
population assigned to the public free Access Terrassa Health Consortium.
Drug: Antihistamine
Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of
survival among patients previously treated with
Other Name: Antihistamine as crhonic treatment and COVID19 infection.
Drug: Amantadine
Observation of the rate of COVID19 infection, the rate of hospitalization and the rate of
survival among patients previously treated with amantadine
Other Name: Amantadine as chronic treatment and COVID19 infection.
Inclusion Criteria: Patients having chronic treatment with antihistamines or amantadine -
Exclusion Criteria: None
-
Hospital de Terrassa
Terrassa, Barcelona, Spain
Hospital of Terrassa
Terrassa, Barcelona, Spain
Anna Puigdellivol, Ph.D
34-93-5884555
apuigdellivol@cst.cat
Anna Puigdellívol, PhD, Principal Investigator
Terrassa Health Consortium